2021 AMR Preparedness Index
The AMR Preparedness Index is the first-of-its-kind evaluation of how the governments of the 11 largest global economies are living up to their commitments to address antimicrobial resistance (AMR).
Read more
Step 1 of the biopharmaceuticals 5-step plan to address vaccine equity A number of countries with access to sufficient doses to vaccinate their own populations have pledged 1 billion doses so far for low- and middle-income (LMIC) countries in 2021 and 2022. We now need to ensure those pledges are realized and vaccines reach those...
Read moreIn light of the recent G7 Summit 2021, where the COVID-19 pandemic was understandably the overarching point of discussions, I was reminded about the key role our industry is playing in this health and economic crisis. This pandemic, the like of which has not been seen in over 100 years, has cost too many lives...
Read moreThe AMR Preparedness Index is the first-of-its-kind evaluation of how the governments of the 11 largest global economies are living up to their commitments to address antimicrobial resistance (AMR).
Read more
22 June – Paris/Geneva/London – Ministers of Health from four African countries (Algeria, Democratic Republic of Congo, Egypt and Cabo Verde), representatives from international organizations, patient groups and the pharmaceutical industry reiterated today at a high-level roundtable event the urgency of establishing a regulatory authority across Africa, especially in the context of the COVID-19 pandemic....
Read moreThe Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, held their first face-to-face meeting since December 2019 in Brussels on Monday 21 and Tuesday 22 June, to discuss global health challenges and public health policies impacting biomedical innovation.
Read moreIFPMA welcomes the opportunity to address this meeting of the Essential Medicines List (EML) Expert Committee, and we take this occasion to also congratulate the World Health Organization (WHO) for the progress made over 44 years in the iterations of the Essential Medicines List. IFPMA represents over 30 leading global biopharmaceutical companies and 50 national...
Read moreThis oped was originally published on in the Down to Earth (16-30 June 2021 Edition). Scarcity of raw materials and trade barriers could dent hopes for 10 billion vaccines produced by end of 2021 Back in March 2020, vaccine innovator companies started working on how they would set up manufacturing and the supply chains produce...
Read moreOriginal article published on Taggesspigel on 15 June 2021. Mr Cueni, of all things, the COVID-19 pandemic, triggered by a virus, could further fuel the development of resistance in bacteria: many Covid 19 patients in hospitals are given antibiotics unnecessarily. G-7 health ministers are warning of a “creeping pandemic” and have been pushing for the...
Read moreAt the 3 June meeting, the life science industry leaders agreed to join forces with governments to step up collective efforts to ensure the world is better prepared to tackle future global pandemics.
Read moreG7 country dose sharing announcements on the back of the G20 pledges combined with vaccine makers commitment to make available 3,5 billion extra doses are an important starting point towards achieving vaccine equity. Innovative vaccine manufacturers and biotech companies at the forefront producing COVID-19 vaccines are confident if scarcity of raw materials and trade barriers...
Read more